Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)

NCT07758218 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT07758218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07758218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2029
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, allogenic stem cell transplantation, chronic myeloid leukemia, lymphoid malignancies, myelodysplastic syndrome, myeloid malignancies